<DOC>
	<DOC>NCT01042392</DOC>
	<brief_summary>This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.</brief_summary>
	<brief_title>Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Outpatients &gt; 18 years Male or female patients. Female patients must have been either postmenopausal for one year, surgically sterile, or using effective contraceptive methods Patients with essential hypertension, previously treated with an antihypertensive singledrug therapy, either uncontrolled or intolerant. BP thresholds at visit 1: For patients previously treated and uncontrolled: 140≤ office SBP&lt;180 mmHg For patients previously treated, controlled but intolerant: office SBP≥130 mmHg BP thresholds at visit 2 (for all patients): 160≤office SBP&lt;180 mmHg AND 155≤home SBP&lt;175 mmHg (3day period of home blood pressure monitoring just before randomization) Women of childbearing potential not using any effective methods of contraception Severe hypertension (office BP ≥ 180/110 mmHg) Impossibility to stop abruptly previous antihypertensive treatments at visit 1 Patients previously untreated or patients treated with two or three antihypertensive medications History or evidence of a secondary form of hypertension History of hypersensitivity to ACEi or renin inhibitors History of heart failure, stroke or coronary heart disease Serum potassium ≥ 5.2 mmol/l Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Moderate systolic hypertension - adults - aliskiren -ramipril</keyword>
</DOC>